Atea Pharmaceuticals (AVIR) held its First Quarter 2026 Financial Results and Business Update Conference Call, providing insights into recent performance and future plans. Executives shared updates, with a press release issued earlier detailing key discussion points. Slides accompanying the call are available in the Investors section at ir.ateapharma.com.
Key Company Participants
- Jonae Barnes, Senior Vice President of Investor Relations & Corporate Communications
- Jean-Pierre Sommadossi, Founder, Chairman, CEO & President
- Janet Hammond, Chief Development Officer
- Maria Horga, Chief Medical Officer
- John Vavricka, Chief Commercial Officer
- Andrea Corcoran, CFO, Executive VP of Legal & Secretary
Conference Call Analysts
- Jonathan Miller, Evercore ISI Institutional Equities, Research Division
- Selena Zhang, Morgan Stanley, Research Division
- Tsan-Yu Hsieh, William Blair & Company L.L.C., Research Division
Opening Remarks
The operator opened the call, welcoming participants and providing instructions for questions. Jonae Barnes then addressed attendees: “Good afternoon, everyone, and welcome to Atea Pharmaceuticals’ First Quarter 2026 Financial Results and Business Update Conference Call.”
Barnes introduced the leadership team, including CEO Jean-Pierre Sommadossi, Chief Development Officer Janet Hammond, Chief Commercial Officer John Vavricka, Chief Medical Officer Dr. Arantxa Horga, and CFO Andrea Corcoran, all available for the Q&A session.
Forward-Looking Statements
Barnes reminded participants of forward-looking statements discussed during the call, which carry risks and uncertainties. These are detailed in the day’s press release and the company’s recent Securities and Exchange Commission filings.
